Octa-guanidine morpholino restores dystrophin expression in cardiac and skeletal muscles and ameliorates pathology in dystrophic mdx mice.
Steric-block antisense oligonucleotides (AONs) are able to target RNAs for destruction and splicing alteration. Reading frame restoration of the dystrophin transcript can be achieved by AON-mediated exon skipping in the dystrophic mdx mouse model. However, simple, unmodified AONs exhibit inefficient delivery systemically, leading to dystrophin induction with high variability in skeletal muscles and barely detectable in cardiac muscle. Here, we examined a Morpholino oligomer conjugated with a dendrimeric octaguanidine (Vivo-Morpholino) and demonstrated that the delivery moiety significantly improved dystrophin production in both skeletal and cardiac muscles in mdx mice in vivo. Single intravenous (IV) injections of 6 mg/kg Vivo-MorpholinoE23 (Vivo-ME23) generated dystrophin expression in skeletal muscles at the levels higher than the injection of 300 mg/kg unmodified ME23. Repeated injections at biweekly intervals achieved near 100% of fibers expressing dystrophin in skeletal muscles bodywide without eliciting a detectable immune response. Dystrophin protein was restored to approximately 50 and 10% of normal levels in skeletal and cardiac muscles, respectively. Vivo-Morpholinos showed no signs of toxicity with the effective dosages and regime, thus offering realistic prospects for the treatment of a majority of Duchenne muscular dystrophy (DMD) patients and many other diseases by targeting RNAs.
Wu
Bo
B
Department of Neurology, McColl-Lockwood Laboratory for Muscular Dystrophy Laboratory, Neuromuscular/ALS Center, Carolinas Medical Center, Charlotte, North Carolina 28231, USA.
Li
Yongfu
Y
Morcos
Paul A
PA
Doran
Timothy J
TJ
Lu
Peijuan
P
Lu
Qi Long
QL
D000818:Animals; D015153:Blotting, Western; D003402:Creatine Kinase / Q000097:blood; D016189:Dystrophin / Q000378:metabolism*; D004797:Enzyme-Linked Immunosorbent Assay; D005786:Gene Expression Regulation / Q000187:drug effects*; D007150:Immunohistochemistry; D007274:Injections, Intraperitoneal; D051379:Mice; D018101:Mice, Inbred mdx; D009025:Morpholines / Q000008:administration & dosage / Q000494:pharmacology*; D018482:Muscle, Skeletal / Q000187:drug effects* / Q000378:metabolism*; D009137:Muscular Dystrophy, Animal / Q000473:pathology / Q000628:therapy*; D009206:Myocardium / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction
D016189:Dystrophin; D009025:Morpholines; D003402:Creatine Kinase